PharmacoEconomics

, Volume 26, Issue 10, pp 892–894 | Cite as

The Authors’ Reply

  • Oren Shavit
  • Moshe Leshno
  • Assaf Goldberger
  • Amir Shmueli
  • Amnon Hoffman
Correspondence
  • 18 Downloads

Keywords

Health Benefit Monte Carlo Simulation Risk Aversion True Effect Wrong Decision 

References

  1. 1.
    Gandjour A. Assessing the value of a future study [letter]. Pharmacoeconomics 2008; 26 (10): 891–2PubMedCrossRefGoogle Scholar
  2. 2.
    Shavit O, Leshno M, Goldberger A, et al. It’s time to choose the study design!: net benefit analysis of alternative study designs to acquire information for evaluation of health technologies. Pharmacoeconomics 2007; 25 (11): 903–11PubMedCrossRefGoogle Scholar
  3. 3.
    Hunink M, Glasziou P, Siegel J, et al. Decision making in health and medicine: integrating evidence and values. 1st ed. Cambridge: Cambridge University Press, 2001Google Scholar
  4. 4.
    Folland S, Goodman A, Stano M. Demand for health capital: the economics of health and health care. 5th ed. Upper Saddle River (NJ): Pearson Education, 2007: 137–152Google Scholar
  5. 5.
    Zivin JG. Cost-effectiveness analysis with risk aversion. Health Econ 2001; 10 (6): 499–508PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  • Oren Shavit
    • 1
  • Moshe Leshno
    • 2
    • 3
  • Assaf Goldberger
    • 4
  • Amir Shmueli
    • 5
  • Amnon Hoffman
    • 1
  1. 1.School of PharmacyThe Hebrew University of JerusalemJerusalemIsrael
  2. 2.Sackler Faculty of MedicineTel Aviv UniversityTel AvivIsrael
  3. 3.Faculty of ManagementTel Aviv UniversityTel AvivIsrael
  4. 4.School of Mathematical SciencesTel Aviv UniversityTel AvivIsrael
  5. 5.School of Public HealthThe Hebrew University of JerusalemJerusalemIsrael

Personalised recommendations